by Week 14/22, respectively; at week 52, clinical response and remission were achieved in 48% and 39% of the patients, respectively. Adverse effects were mostly minor and occurred in 30.6% of the patients; infections were reported in 3.4% of the patients. Conclusions: VDZ is efficacious in CD and UC and has a favourable safety profile in RWE studies.
Introduction
Although medical treatment options in inflammatory bowel disease [IBD] have improved dramatically over recent decades with the introduction of anti-tumour necrosis factor [TNF] antibodies, refractory disease still poses a major challenge, with primary non-response occurring in 20-30% of Crohn's disease [CD] and up to 40% of ulcerative colitis [UC] patients. 1 A substantial number of primary responders [as high as 46%] relapse despite continued treatment or dose escalation, with quite a substantial rate of early discontinuation of anti-TNF therapy. 2, 3 Vedolizumab [VDZ] is a humanised monoclonal antibody that exclusively targets the alpha 4 beta 7 integrin, characteristically expressed by gut-homing lymphocytes, and modulates gut inflammation by limiting lymphocyte recruitment from the blood to the intestinal lamina propria.
Vedolizumab [VDZ] demonstrated efficacy in Crohn's disease and ulcerative colitis in the pivotal GEMINI trials. [4] [5] [6] [7] In the GEMINI I study [UC] , the response rate to VDZ was significantly higher than to placebo at both 21 .6% for placebo). 6 The Gemini III study included CD patients who previously failed anti-TNF therapy. The rates of remission at Week 6 were not significantly different from with placebo (15.2% vs 12.1% [p = 0.4]), although clinical superiority over placebo was detectable at Week 10 (26.6% vs 12.1% [p = 0.001]). 7 Long-term follow-up data from the GEMINI LTS [long-term safety] open-label extension trial are also becoming available. Among UC patients who responded to VDZ induction and had available data, 88% and 96% were in clinical remission after 104 and 152 weeks, respectively; for CD patients, 83% and 89% were in clinical remission at the same time points. 9 Safety data from all GEMINI trials demonstrated an overall rate of adverse events that was similar to that with placebo. There was no increased risk of malignancy. A Cochrane systematic review of VDZ for UC reported no significant differences between VDZ and placebo for any adverse event or serious adverse event. Serious clostridial infections, sepsis and tuberculosis were reported infrequently [≤ 0.6% of patients], with upper respiratory tract infections accounting for more than half of the total infections reported. 10 Despite the abundance of randomized controlled trial [RCT]-originated data, multiple knowledge gaps still remain. Primarily, all RCTs have stringent inclusion criteria and tend to exclude certain groups of patients such as patients with isolated small bowel disease inaccessible to ileocolonoscopy, patients with multiple comorbidities, and other special populations such as pregnant women, those with organ transplant, and paediatric and elderly patients. 11, 12 A substantial proportion of the patients treated with biologics could not have been included in a clinical trial due to these limitations. In addition, multiple secondary outcomes such as postoperative recurrence, healing of perianal fistula and response of extra-intestinal manifestations frequently remain beyond the scope of major RCTs. Real-world experience series may shed light on those and additional issues, including previously undetected safety signals [primarily infections and malignancies]. To date, several real-world data series have been published demonstrating efficacy and safety comparable to those reported in the randomised controlled trials. In addition, several case reports and case series addressing specific clinical conditions and subpopulations are available.. 4, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The aim of our review was to summarise the currently available knowledge and to perform a pooled analysis of the efficacy and safety of VDZ in IBD patients, as reported by the real-world studies.
Methods
A structured search of the Pubmed and Embase database was performed to identify all studies that describe real-world experience with VDZ. For the purposes of the pooled analysis of efficacy and safety, only reports published in complete form in peer-reviewed literature were included. We extracted the baseline characteristics, efficacy, and safety data from the manuscripts. We addressed induction data as results at Weeks 6 and 12/14/22, depending on the study definition. Efficacy data for week 52/54 were defined as maintenance results. 
Statistical methods
The outcome measures were calculated as pooled proportions of patients [with 95% confidence intervals] responding VDZ treatment at various points in time, and the pooled proportions of patients with complications of interest. The fixed effects [Mantel-Haenszel] and random effects [DerSimonian-Laird] models were used for pooling, depending on heterogeneity. Heterogeneity was determined using the Q statistic of I 2 which describes the percentage of total variation across studies attributable to heterogeneity rather than chance. An I 2 value greater than 50% was taken to represent significant statistical heterogeneity, in which case the random effects model was applied; if studies were relatively homogeneous, the fixed effects model was used. 27 A minimum of three studies were required for each analysis. Statistical analyses were carried out using the 'meta' and 'metafor' packages 28 in R statistical software version 3.3.1 [R Foundation for Statistical Computing, Vienna, Austria].
Significant statistical heterogeneity was assessed by examining the forest plots for obvious outliers and by conducting subgroup analyses, chiefly differentiating patients with CD from those with UC. Although outlier studies could not always be eliminated due to the small numbers of studies in some subgroup analyses, this would be representative of 'real-world' experience where responses may vary widely across centres and patient groups. When quantitative analysis was impossible due to a small number of patients, we performed a systematic narrative review of the available data for special conditions and populations [postoperative, pregnant, and elderly patients, paediatric patients].
Results
Through the literature search, 297 publications were obtained. Nine adult (1565 [571 UC, 994 CD] patients) [13] [14] [15] [16] [17] [18] [19] 26, 29 and two pediatric studies (73 [27 UC, 46 CD patients]) 20, 30 were identified [ Figure 1 ]. An additional study was excluded from the pooled analysis, which described the efficacy of VDZ at Week 54 including only Week 14 responders. 31 Only adult studies were included in the pooled analysis, as the number of paediatric studies was too small.
Clinical characteristics of patients included in RWE studies
Of the CD population 37%, and of the UC/inflammatory bowel disease unclassified [ 
UC: efficacy

Induction
Data for clinical response and remission at Week 6 for UC patients were available from four studies enrolling a total of 288 UC/IBD-U patients. [14] [15] [16] 29 
Endoscopic response and mucosal healing
Two studies reported endoscopic response and mucosal healing to VDZ, enrolling together 148 CD patients and 29 UC patients. 17, 18 Mucosal healing for CD was defined as absence of mucosal ulcerations or erosions in both studies. Mucosal disease activity in UC was determined using the endoscopic Mayo score. 33 Dulai et al. reported cumulative rates of mucosal healing of 21% and 67% after 6 and 12 months of therapy, respectively. 18 Vivio et al. reported mucosal healing in 30% and 69% in CD and UC, respectively, by 52 weeks. 17 
Biomarker response during vedolizumab treatment
Decrease in C-reactive protein [CRP] levels in patients achieving clinical remission with VDZ treatment was reported by most studies; however the change was frequently not statistically significant. 15, 16, 32, 34 Steady decline and improvement of faecal calprotectin in responders was demonstrated in all studies reporting calprotectin values for both CD and UC. 15, 19, 32 
Predictors of clinical response
Eight studies assessed predictors of initial response to VDZ. [14] [15] [16] 18, 19, 29, 31, 32 Smoking history, perianal disease, and previous anti-TNF exposure were associated with a lower likelihood of achieving remission. 18, 19 Higher baseline disease severity and high CRP levels at treatment onset were associated with a lower likelihood of remission later in several studies. 13 response on multivariate analysis; for UC, no such predictors could be identified. 
Extra-intestinal manifestations
Safety
A total of 390 [30.6%] adverse events [AEs] were reported in the real-world studies. The three most common adverse events in realworld data were myalgia and arthralgia, followed by nasopharyngitis, infection, and skin eruption [ 
250
T case of severe disseminated histoplasmosis was reported in a patient treated concomitantly with VDZ and methotrexate [MTX] . The patient recovered with antifungal treatment and required prolonged hospitalisation. 17 One case of pseudomonas meningitis in a young CD patient treated concomitantly with azathioprine [AZA] and budesonide was reported as a separate case. 36 Neurological AEs included paraesthesias in 15 [1.4%] patients 37 and a transient hearing loss in one patient. 13 Infusion reactions occurred in eight [0.006%] patients.
Death was reported in 3/1640 [0.001%] patients. In one case, a 69-year-old patient with severe pancolitis, who received VDZ with full dose of corticosteroids, died from complications of necrotising fasciitis and colonic perforation during colonoscopy. 13 The other one was a 72-year-old patient who developed cytomegalovirus [CMV] colitis 14 weeks after VDZ first exposure, and died from complications of sepsis and acute kidney injury. 17 The third was a 39-year-old female with severe penetrating ileocolonic CD, who developed postoperative septic shock. Exposure to VDZ was a significant predictor of postoperative SSI on multivariate analysis [p < 0.001]. 38 An additional study from the same cohort addressed UC patients only and included 88 patients who received VDZ and 62 who received anti-TNFα within 12 weeks of surgery. More vedolizumab-treated patients had superficial surgical site infections [p = 0.047] and mucocutaneous separation at the ileostomy [p = 0.047], but there was no difference in the overall surgical infectious complication rate, deep space surgical site infections, or need for reoperation within 30 days.
After ileal pouch-anal anastomosis, there was a higher rate of intra-abdominal abscesses [31.3% vs 5.9%] and mucocutaneous separation [18.8% vs 0%] in the vedolizumab group compared with the anti-TNFα group, although the difference did not reach statistical significance. 39 Two other currently available series did not demonstrate an increased risk of postsurgical complications with preoperative VDZ treatment. Yadav et al. compared the rate of surgical complications in patients who received VDZ, anti-TNFs, and non-biological therapy within 4 weeks of surgery, using propensity score matching. 40 The study included 443 patients [64 on vedolizumab, 129 on anti-TNF-α agents, and 250 on non-biological therapy]; 32% experienced postoperative complications. The risks of postoperative complications were not different among patients in either treatment group. 40 An additional recent large Belgian singlecentre study included 170 UC patients; of these, 20% received VDZ and 35% anti-TNFs within 8 weeks before proctocolectomy with ileoanal pouch-anal anastomosis. No significant difference could be observed between different treatment categories in development of short-term postoperative complications. 41 It is possible that the discrepancy in the results stems from additional confounders such as disease severity, surgical technique, definitions of complications or patient selection. Further large studies are needed to clarify whether VDZ indeed poses any increased risk of postsurgical complications, and whether any additional caution in the management of perioperative IBD patients on VDZ should be required.
Pregnancy
Our knowledge pertaining to the safety of VDZ in pregnancy is currently very limited. A recent paper summarised the experience from the GEMINI programme. Across six studies, there were 27 pregnancies in female participants and 19 pregnancies in partners of male participants. Eleven live births, five elective terminations, four spontaneous abortions, and four undocumented outcomes were reported. A congenital corpus callosum agenesis anomaly was reported in one live birth from a healthy volunteer with extensive obstetric history, exposed to single-dose VDZ 79 days before estimated conception. Of 19 pregnancies in partners of male participants, there were 11 live births, two spontaneous abortions, three elective terminations, and three undocumented outcomes. Post-marketing reports recorded 81 pregnancies, resulting in four live births, 11 spontaneous abortions, and 66 pregnancies that were ongoing or reported undocumented outcomes. 42 In addition, three cases of uneventful pregnancies in patients treated with VDZ 21, 24 were published so far. Importantly, VDZ crosses the placenta in similarity to other IgG1 antibodies, and can be detected in the cord as well as in the infant blood. 43 Results from the PIANO registry demonstrate that the serum level of VDZ in an infant at birth is approximately half of that detected in the maternal serum. 44 Although the role of alpha-4 beta 7 signalling in embryonic and infant development is unclear, animal studies using supratherapeutic doses of VDZ showed no signs of teratogenicity, stillbirth, impaired intrauterine growth, or postnatal physical development up to 6 months of age. 45 Due to a scarcity of available safety data in pregnancy, VDZ should be used during pregnancy only if the benefits to the mother outweigh the risks to the mother/unborn child. 42 Importantly, no data regarding the safety of lactation or safety of vaccinations in a newborn exposed to VDZ in utero are currently available.
Ostomy and pouch patients
A single series reported the outcomes of VDZ patients with ileostomy and ileo-anal pouches. 16 
Paediatric patients
To date, two paediatric case series were published in complete form. Conrad et al. described their experience with 21 patients with previous failure of anti-TNF treatment. 20 Clinical response was observed in 6/19 [31.6%] at Week 6 and in 11/19 [57.9%] by Week 22; steroid-free remission was achieved in 20% of the patients by Week 22. 20 A larger multicentre case series included 52 paediatric patients [58% CD and 42% UC]. Week 14 remission rates for UC and CD were 76% and 42%, respectively. At Week 22, anti-TNF naive patients had higher remission rates than TNF-exposed patients [100% versus 45%, p = 0.04]. 30 The reported adverse events in both cohorts were minor and similar to those reported in the adult series.
Elderly patients
The evidence on the efficacy and safety of VDZ in the elderly was addressed in a single case series published in letter form. Navaneethan et al. 23 23 These results are comparable to the general RWE data. 
Vedolizumab in patients after liver transplantation
A recent case series published in letter form addressed the use of VDZ in IBD patients after liver transplantation. 25 Ten patients were included; the median duration of follow-up was 13.1 months. The rates of response were 70% and 60% after 6 and 12 months, respectively. All patients were on corticosteroids at treatment onset. During the exposure to VDZ, five patients experienced a total of 11 infections [four cholangitis, four Clostridium difficile colitis, two empyema, and one pneumonia], probably reflecting a higher degree of immunosuppression in these patients. An additional case series described the results of treatment in five IBD patients following liver transplation for primary sclerosing cholangitis. 46 Clinical response was achieved in 3/5 patients [60%], two of whom were in clinical remission with mucosal healing after 14 weeks of treatment. Two patients were referred for colectomy. VDZ was well tolerated. During the period of follow-up, median 6.8 months [range 6.0-6.9], there were no reported opportunistic infections and liver synthetic function was stable. 46 
Therapeutic drug monitoring with vedolizumab
Although higher levels of infliximab and adalimumab were associated with clinical remission and mucosal healing in both UC and CD, [47] [48] [49] data regarding the pharmacokinetics of VDZ are still scarce. The GEMINI trials have demonstrated that VDZ drug levels were positively associated with clinical response at Week 6, especially among UC patients. Trough levels have been also shown to associate with endoscopic score among UC patients. However, drug levels have not been evaluated in relation to clinical or endoscopic outcomes at further time points. In a recent French publication, VDZ serum concentrations were not significantly different between responders and non-responders, although lower Week 6 trough levels [below 19.0 μg/mL] were associated with the need for interval shortening during the course of therapy. 29 Recent data from two unrelated 'realworld' cohorts, presented in abstract form, demonstrated a correlation between VDZ levels and biomarker response [CRP] . 50, 51 Anti-VDZ antibodies [AVA] have been described, with varying formation rates. In GEMINI, AVA were reported in 4% of the patients; 0.5-1% AVA were persistent [two or more consecutive samples]. A sub-analysis of the VDZ phase 2 study included 37 UC patients and demonstrated a higher rate of 11% AVA, 5.5% persistent. 52, 53 An additional study of 39 healthy volunteers who received a single VDZ infusion demonstrated a 54% rate of AVAs, 28% of them persistent. 54 Clinical relevance of AVA has not been established.
To conclude, preliminary data, which consist mostly of the GEMINI trials and sub-analyses, demonstrate a modest association between trough VDZ levels and clinical and biomarker response, more so in UC patients. AVA have been described with varying incidence rates, although data of their effect on clinical outcome are limited. Further large-scale studies are required in order to establish whether therapeutic drug monitoring [TDM] of VDZ therapy would improve patient care.
Discussion
The current pooled analysis of the RWE data suggests that the real-world efficacy and safety of VDZ are comparable to what was reported by GEMINI studies.
The effect of VDZ appears to be cumulative, with a longer duration of treatment being associated with higher rates of response. The optimal timing for definition of primary response/non-response is currently unclear, as the effect of VDZ may be somewhat delayed in some patients; it appears diligent to wait for at least 14 weeks and sometimes even longer before discontinuation of treatment, attempting interval shortening to q4 weeks in non-responders or partial responders.
One of the most striking differences between the RCT and the RWE populations is the percentage of anti-TNF naive patients. In the RWE series, the number of anti-TNF naive patients is very low [8.5%] , with a vast majority of the included patients previously failing at least one, and frequently two or more, previous biologics. GEMINI 1 included 48.1% anti-TNF naive UC patients, and GEMINI II 38.2% anti-TNF naive patients. 4, 6 In fact, the CD population in the RWE series is much closer to that of GEMINI III, which included only anti-TNF experienced patients. 7 Very limited data published in abstract form suggest that the response in anti-TNF naive patients may be substantially better; however, further data are required. 13 Importantly, the response to anti-TNFs appears to be significantly better in biologic-naive patients as well. 55, 56 Real-life series demonstrate the utility of VDZ in additional patient populations that were excluded or under-represented in RCTs. VDZ appears to be efficacious in paediatric and elderly patients; very preliminary data suggest efficacy in patients after liver transplantation and patients with ostomy/ileo-anal pouches.
The safety of VDZ in pregnancy requires thorough evaluation. Currently available data include pregnancies during participation in the GEMINI trials, preliminary results from the PIANO registry, and scarce case reports. Additional data are expected from the PIANO registry and additional retrospective series.
To date, there is no evidence pointing to a potential association of VDZ treatment with malignancy. However, significantly longer duration of follow-up is required in order to draw any meaningful conclusion on this matter.
The benefit of combination therapy with immunomodulators is still unclear. For infliximab, the superior clinical efficacy of combination therapy is well established 57, 58 ; for adalimumab, the results are still inconclusive. 48, 59, 60 The clinical benefit of combination therapy is most likely a result of diminished immunogenicity and suppression of anti-drug antibodies. 47, 49, 51, [61] [62] [63] [64] In GEMINI studies, combination therapy was not associated with improved outcomes. [4] [5] [6] [7] Importantly, the correlation between vedolizumab trough levels and clinical response appears to be less robust than for anti-TF biologics, although the data are still very limited; moreover, the prevalence of anti-vedolizumab antibodies appears to be quite low and their neutralising capacity and impact on trough levels and clinical outcomes are unclear. Currently, a single study suggested a benefit for combination therapy with vedolizumab 31 ; additional studies are required to determine whether this strategy should be recommended.
There are multiple limitations to retrospective real-life studies. Primarily, there was a significant heterogeneity in study design, including the definitions of response and remission. Most of the studies used clinical scores, but Dulai et al. 18 reported PGA-based outcomes; and Kopylov et al. 13 used a combination of clinical scores, and PGA when clinical scores were unavailable. Dulai et al. 18 reported the data retrospectively, whereas other studies used a prospective approach. Moreover, all the included series, with the exception of Vivio et al., included multicentre patient cohorts; such an approach may result in significant differences in clinical approaches and decision-making, when multiple physicians were involved in the care of the patients. Such heterogeneity limits the interpretation of both the original studies and the pooled analysis.
Importantly, endoscopic data were available from two studies only. 17, 18 This is one of the main drawbacks of RWE data in comparison with RCT data, as endoscopies were not routinely scheduled and performed in these series and the data were only available for a small subgroup biased by selection of these patients for endoscopy. Moreover, the endoscopy results were reported retrospectively in the larger series of the two. 36 Results pertaining to treatment of EIMs are very limited for all therapeutic agents, including anti-TNFs, immunomodulators, and ustekinumab; aside of a single prospective study with adalimumab, 65 all other reports are retrospective and very limited by absence of a verified quantitative method for assessment of response. [66] [67] [68] In summary, VDZ appears to be effective in UC and CD in realworld studies in multiple populations, including those traditionally outside the scope of RCTs. Additional postmarketing data are required for a multitude of efficacy and safety issues such as extraintestinal manifestations, healing of perianal fistulas, safety in pregnancy and lactation, perioperative complications, and more.
